BIOMARIN PHARMACEUTICAL INC
BMRNAPI behind this page
BMRN Q1 2026 request
Playground key active
/api/financials?ticker=BMRN&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 766,208 | 745,145 | +2.8% |
Show Product Lines breakouts |
|||
| ALDURAZYME | 36,742 | 48,977 | -25.0% |
| ALDURAZYME · Sales Channel Through Intermediary | 36,742 | 48,977 | -25.0% |
| BRINEURA | 47,104 | 40,362 | +16.7% |
| KUVAN | 23,880 | 25,136 | -5.0% |
| NAGLAZYME | 130,074 | 114,290 | +13.8% |
| PALYNZIQ | 89,558 | 93,269 | -4.0% |
| Product | 760,078 | 734,644 | +3.5% |
| Products excluding ALDURAZYME · Europe | 218,836 | 229,578 | -4.7% |
| Products excluding ALDURAZYME · Latin America | 108,164 | 88,282 | +22.5% |
| Products excluding ALDURAZYME · Rest of world | 153,392 | 126,113 | +21.6% |
| Products excluding ALDURAZYME · Sales Channel Directly To Consumer | 723,336 | 685,667 | +5.5% |
| Products excluding ALDURAZYME · US | 242,944 | 241,694 | +0.5% |
| ROCTAVIAN | 2,636 | 10,510 | -74.9% |
| Royalty and other revenues | 6,130 | 10,501 | -41.6% |
| VIMIZIM | 210,204 | 188,346 | +11.6% |
| VOXZOGO | 219,880 | 213,754 | +2.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 766,208 | 745,145 | +2.8% |
| Cost of Revenue | 194,999 | 151,558 | +28.7% |
Show Business Segments breakouts |
|||
| Reportable Segment | 194,999 | 151,558 | +28.7% |
| Total Costs & Expenses | 636,568 | 521,252 | +22.1% |
| Research & Development | 178,796 | 158,731 | +12.6% |
Show Product Lines breakouts |
|||
| Later-stage clinical programs · Reportable Segment | 36,177 | 14,291 | +153.1% |
| Marketed products · Reportable Segment | 55,328 | 53,970 | +2.5% |
| Research and early pipeline · Reportable Segment | 87,291 | 90,470 | -3.5% |
| Sales & Marketing (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 124,927 | 102,531 | +21.8% |
| General & Administrative (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 133,363 | 103,585 | +28.7% |
| Selling, General & Administrative | 258,290 | 206,116 | +25.3% |
| Operating Income | 129,640 | 223,893 | -42.1% |
| Interest Expense | -14,958 | -2,863 | -422.5% |
| Interest Income | 22,560 | 19,013 | +18.7% |
| Income Before Taxes | 141,203 | 238,089 | -40.7% |
| Income Tax Expense (Benefit) | 35,676 | 52,403 | -31.9% |
| Comprehensive Income | 114,763 | 143,184 | -19.8% |
| Other Comprehensive Income | 9,236 | -42,502 | +121.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 13,007 | -43,591 | +129.8% |
| Accumulated Net Unrealized Investment Gain Loss | -3,771 | 1,089 | -446.3% |
| Accumulated Other Comprehensive Income | 9,236 | -42,502 | +121.7% |
| EPS (Basic) | 0.55 | 0.97 | -43.3% |
| EPS (Diluted) | 0.54 | 0.95 | -43.2% |
| Wtd Avg Shares (Basic) | 192,497 | 190,967 | +0.8% |
| Wtd Avg Shares (Diluted) | 197,671 | 196,474 | +0.6% |
| Interest Expense | 9,571 | 2,387 | +301.0% |
| Net Income Loss Available To Common Stockholders Basic | 105,527 | 185,686 | -43.2% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,222,435 | — | — |
| Accounts Receivable | 903,914 | 739,177 | +22.3% |
Show Major Customers breakouts |
|||
| Sanofi | 152.6 | 105 | +45.3% |
| Inventory | 1,273,221 | 1,274,848 | -0.1% |
| Other Assets Current | 205,500 | 181,545 | +13.2% |
| Total Current Assets | 4,605,070 | 3,467,905 | +32.8% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 958,071 | 1,032,613 | -7.2% |
| Intangible Assets Net Excluding Goodwill | 204,662 | 247,346 | -17.3% |
| Goodwill | 196,199 | 196,199 | 0.0% |
| Deferred Tax Assets | 1,500,598 | 1,460,566 | +2.7% |
| Restricted Cash Equivalents Noncurrent | 850,000 | — | — |
| Other Non-Current Assets | 276,416 | 235,654 | +17.3% |
| Total Assets | 8,591,016 | 7,147,007 | +20.2% |
| Intangible Assets | 204,662 | 247,346 | -17.3% |
| Current Liabilities | |||
| Accounts Payable And Accrued Liabilities Current | 793,152 | 628,213 | +26.3% |
| Total Current Liabilities | 793,152 | 628,213 | +26.3% |
| Non-Current Liabilities | |||
| Long-Term Debt | 1,430,282 | — | — |
Show Debt Instrument breakouts |
|||
| 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes) · Senior Subordinated Notes | 597,689 | — | — |
| 5.5% senior unsecured notes due in February 2034 (the 2034 Notes) · Senior Notes | 832,593 | — | — |
| Other Non-Current Liabilities | 155,475 | 129,685 | +19.9% |
| Total Liabilities | 2,378,909 | 1,353,548 | +75.8% |
| Stockholders' Equity | |||
| Common Stock | 193 | 192 | +0.5% |
| Additional Paid In Capital Common Stock | 5,966,868 | 5,794,302 | +3.0% |
| Common Stock Issued Employee Stock Trust | -10,450 | -11,177 | +6.5% |
| Accumulated Other Comprehensive Income | -4,237 | 19,151 | -122.1% |
| Retained Earnings | 259,733 | -9,009 | +2983.0% |
| Total Stockholders' Equity | 6,212,107 | 5,793,459 | +7.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -4,237 | 16,233 | -126.1% |
| Accumulated Other Comprehensive Income | -4,237 | 19,151 | -122.1% |
| Additional Paid In Capital | 5,966,868 | 5,794,302 | +3.0% |
| Common Stock | 193 | 192 | +0.5% |
| Deferred Compensation Share Based Payments | -10,450 | -11,177 | +6.5% |
| Retained Earnings | 259,733 | -9,009 | +2983.0% |
| Total Liabilities & Equity | 8,591,016 | 7,147,007 | +20.2% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 105,527 | 185,686 | -43.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 105,527 | 185,686 | -43.2% |
Show Equity Components breakouts |
|||
| Retained Earnings | 105,527 | 185,686 | -43.2% |
| Depreciation & Amortization | 16,411 | 22,069 | -25.6% |
| Amortization Of Financing Costs And Discounts | 6,086 | 660 | +822.1% |
| Accretion Amortization Of Discounts And Premiums Investments | -455 | -1,362 | +66.6% |
| Stock-Based Compensation | 43,458 | 37,700 | +15.3% |
| Deferred Income Taxes | 9,220 | 28,429 | -67.6% |
| Foreign Currency Transaction Gain Loss Unrealized | 6,710 | -10,026 | +166.9% |
| Other Non-Cash Items | -5,374 | -1,267 | -324.2% |
| Change in Accounts Receivable | -7,159 | -57,590 | +87.6% |
| Change in Inventory | 44,490 | -24,335 | +282.8% |
| Increase Decrease In Other Current Assets | -11,551 | -6,327 | -82.6% |
| Increase Decrease In Other Noncurrent Assets | 1,484 | -1,624 | +191.4% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 3,100 | -2,655 | +216.8% |
| Increase Decrease In Other Operating Liabilities | 8,704 | 2,069 | +320.7% |
| Net Cash from Operations | 220,651 | 174,394 | +26.5% |
| Investing Activities | |||
| Capital Expenditures | -20,923 | -16,768 | -24.8% |
| Proceeds From Sale Maturity And Collections Of Investments | 767,277 | 77,804 | +886.2% |
| Payments To Acquire Investments | -25,792 | -89,274 | +71.1% |
| Other Investing Activities | 4,966 | — | — |
| Net Cash from Investing | 725,528 | -28,238 | +2669.3% |
| Capital Expenditures Incurred But Not Yet Paid Fixed Assets | 11,200 | 4,470 | +150.6% |
| Capital Expenditures Incurred But Not Yet Paid Intangible Assets | 4,481 | — | — |
| Financing Activities | |||
| Tax Withholding for Share Compensation | -28,180 | -38,779 | +27.3% |
| Proceeds From Issuance Of Debt | 850,000 | — | — |
| Debt Issuance Costs | -8,653 | — | — |
| Net Cash from Financing | 813,167 | -38,779 | +2196.9% |
| Amortization of Financing Costs | 279 | 27 | +933.3% |
| Supplemental | |||
| Income Taxes Paid | 14,644 | 10,388 | +41.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1,410 | -1,416 | +199.6% |
| Net Change in Cash | 1,760,756 | 105,961 | +1561.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,072,435 | 1,048,803 | +192.9% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.